Stayble Therapeutics’ STA363 receives positive phase 1b results
Stayble Therapeutics AB ("Stayble" or the "Company") announces positive results from the Company's clinical phase 1b study in lumbar disc herniation (LDH). The study met its primary safety and tolerability endpoint. Additionally, STA363-treated patients showed a statistically significant reduction in disc volume compared to placebo-treated patients.The study met its primary endpoint with an established favorable safety profile. Only a few adverse events (AE) and no sustained serious adverse events (SAE) related to STA363 were recorded during the study. Data show a statistically